Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 228,396
  • Shares Outstanding, K 167,938
  • Annual Sales, $ 0 K
  • Annual Income, $ -101,170 K
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.93
Trade XFOR with:

Options Overview Details

View History
  • Implied Volatility 292.95% ( +72.16%)
  • Historical Volatility 111.92%
  • IV Percentile 99%
  • IV Rank 99.58%
  • IV High 294.03% on 09/01/23
  • IV Low 34.35% on 09/13/23
  • Put/Call Vol Ratio 0.04
  • Today's Volume 790
  • Volume Avg (30-Day) 1,584
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 29,973
  • Open Int (30-Day) 29,916

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 6
  • High Estimate -0.13
  • Low Estimate -0.22
  • Prior Year -0.16
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +14.95%
on 04/10/24
1.6000 -23.13%
on 04/03/24
-0.2300 (-15.75%)
since 03/22/24
3-Month
0.7004 +75.61%
on 01/25/24
1.6000 -23.13%
on 04/03/24
+0.4812 (+64.26%)
since 01/23/24
52-Week
0.5723 +114.92%
on 12/12/23
2.5750 -52.23%
on 06/13/23
-0.2200 (-15.17%)
since 04/21/23

Most Recent Stories

More News
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 9.60 (-3.23%)
KA : 0.6698 (+5.50%)
APRE : 5.37 (+4.88%)
XFOR : 1.2300 (-9.56%)
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

XFOR : 1.2300 (-9.56%)
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board

Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global,...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

Company now focused on advancing lead clinical candidate mavorixafor in chronic neutropenic disorders, including WHIM syndrome Important mavorixafor...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small...

XFOR : 1.2300 (-9.56%)
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

XFOR : 1.2300 (-9.56%)
ACET : 2.10 (+5.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.5233
2nd Resistance Point 1.4567
1st Resistance Point 1.3433
Last Price 1.2300
1st Support Level 1.1633
2nd Support Level 1.0967
3rd Support Level 0.9833

See More

52-Week High 2.5750
Fibonacci 61.8% 1.8100
Fibonacci 50% 1.5737
Fibonacci 38.2% 1.3373
Last Price 1.2300
52-Week Low 0.5723

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar